Should I buy or sell Akero Therapeutics stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Akero Therapeutics in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AKRO shares. View AKRO analyst ratings or view top-rated stocks .

What is Akero Therapeutics' stock price target for 2024?

8 brokers have issued twelve-month target prices for Akero Therapeutics' shares. Their AKRO share price targets range from $33.00 to $58.00. On average, they predict the company's share price to reach $40.86 in the next year. This suggests a possible upside of 147.3% from the stock's current price. View analysts price targets for AKRO or view top-rated stocks among Wall Street analysts .

How have AKRO shares performed in 2023?

Akero Therapeutics' stock was trading at $54.80 at the beginning of 2023. Since then, AKRO shares have decreased by 69.9% and is now trading at $16.52. View the best growth stocks for 2023 here .

When is Akero Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 15th 2024. View our AKRO earnings forecast .

How were Akero Therapeutics' earnings last quarter?

Akero Therapeutics, Inc. (NASDAQ:AKRO) released its earnings results on Monday, November, 13th. The company reported ($0.71) earnings per share for the quarter, missing analysts' consensus estimates of ($0.70) by $0.01.

What ETFs hold Akero Therapeutics' stock?

ETFs with the largest weight of Akero Therapeutics (NASDAQ:AKRO) stock in their portfolio include Simplify Propel Opportunities ETF (SURI) , Invesco Dorsey Wright Healthcare Momentum ETF (PTH) , ALPS Medical Breakthroughs ETF (SBIO) and SPDR S&P Biotech ETF (XBI) . Invesco DWA SmallCap Momentum ETF (DWAS) .

What other stocks do shareholders of Akero Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akero Therapeutics investors own include Fulcrum Therapeutics (FULC) , Kaleido Biosciences (KLDO) , Sorrento Therapeutics (SRNE) , Editas Medicine (EDIT) , Gossamer Bio (GOSS) , Provention Bio (PRVB) , Alector (ALEC) , Micron Technology (MU) , VIVUS (VVUS) .

When did Akero Therapeutics IPO?

(AKRO) raised $75 million in an initial public offering (IPO) on Thursday, June 20th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and Evercore ISI served as the underwriters for the IPO and Roth Capital Partners was co-manager.

Who are Akero Therapeutics' major shareholders?

Akero Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Alkeon Capital Management LLC (6.78%), FMR LLC (4.95%), Adage Capital Partners GP L.L.C. (3.49%), Redmile Group LLC (3.18%), Rock Springs Capital Management LP (2.55%) and Lord Abbett & CO. LLC (1.40%). Insiders that own company stock include Andrew Cheng , Catriona Yale , G Walmsley Graham, Jonathan Young , Kevin Bitterman , Seth Loring Harrison, Skorpios Trust, Timothy Rolph, Tomas J Heyman and William Richard White . View institutional ownership trends .

How do I buy shares of Akero Therapeutics?

Shares of AKRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Akero Therapeutics Stock Price, News & Analysis (NASDAQ:AKRO)

$16.52

+0.42 (+2.61%)

(As of 11/28/2023 ET)

Compare

Today's Range: $15.62
▼
$16.55
50-Day Range: $11.38
▼
$50.58
52-Week Range: $11.25
▼
$58.38

Volume: 676,203 shs
Average Volume: 981,478 shs
Market Capitalization: $920.33 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $40.86

Akero Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 147.3% Upside
$40.86 Price Target
Short Interest: Bearish
11.04% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.75
Upright™ Environmental Score
News Sentiment: 0.11
Based on 4 Articles This Week
Insider Trading: Selling Shares
$3.61 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.81) to ($3.34) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

Medical Sector

238th out of 949 stocks

Pharmaceutical Preparations Industry

99th out of 435 stocks

4.5

Analyst's Opinion

Consensus Rating
Akero Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $40.86, Akero Therapeutics has a forecasted upside of 147.3% from its current price of $16.52.
Amount of Analyst Coverage
Akero Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
11.04% of the outstanding shares of Akero Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Akero Therapeutics has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Akero Therapeutics has recently increased by 4.41%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Akero Therapeutics does not currently pay a dividend.
Dividend Growth
Akero Therapeutics does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Akero Therapeutics has received a 75.57% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Akero Therapeutics is -0.75.

1.7

News and Social Media Coverage

News Sentiment
Akero Therapeutics has a news sentiment score of 0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Akero Therapeutics this week, compared to 3 articles on an average week.
Search Interest
Only 2 people have searched for AKRO on MarketBeat in the last 30 days. This is a decrease of -85% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Akero Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Akero Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,610,819.00 in company stock.
Percentage Held by Insiders
Only 9.69% of the stock of Akero Therapeutics is held by insiders.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Akero Therapeutics are expected to decrease in the coming year, from ($2.81) to ($3.34) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Akero Therapeutics is -7.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Akero Therapeutics is -7.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Akero Therapeutics has a P/B Ratio of 2.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Akero Therapeutics Stock (NASDAQ:AKRO)

Akero Therapeutics, Inc., a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company is also conducting a Phase 2b clinical trial to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

AKRO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AKRO Stock News Headlines

November 23, 2023 | morningstar.com

Akero Therapeutics Inc AKRO

November 23, 2023 | americanbankingnews.com

Akero Therapeutics (NASDAQ:AKRO) Shares Down 3% on Insider Selling

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 22, 2023 | seekingalpha.com

Akero Therapeutics: Deceptively Promising

November 19, 2023 | americanbankingnews.com

FY2023 EPS Estimates for Akero Therapeutics, Inc. (NASDAQ:AKRO) Lowered by Analyst

November 15, 2023 | markets.businessinsider.com

Ed Arce’s Buy Rating for Akero Therapeutics: Anticipated Success with SYNCHRONY Studies and EFX Drug Developments

November 15, 2023 | benzinga.com

Akero Therapeutics Stock (NASDAQ:AKRO) Earnings Dates and Earning Calls

November 14, 2023 | finance.yahoo.com

Akero Therapeutics Inc (AKRO) Reports Q3 2023 Financial Results

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

November 14, 2023 | markets.businessinsider.com

11 Analysts Have This to Say About Akero Therapeutics

November 13, 2023 | benzinga.com

Akero Therapeutics: Q3 Earnings Insights

November 13, 2023 | finance.yahoo.com

Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

November 12, 2023 | stockhouse.com

Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD's The Liver Meeting® 2023

November 10, 2023 | finance.yahoo.com

Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD’s The Liver Meeting® 2023

October 17, 2023 | finance.yahoo.com

Akero Therapeutics to Present at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference

October 13, 2023 | msn.com

UBS Maintains Akero Therapeutics (AKRO) Buy Recommendation

October 12, 2023 | fool.com

Akero Therapeutics (NASDAQ: AKRO)

October 11, 2023 | finance.yahoo.com

Akero Therapeutics' Lead Candidate Potential: Analyst Unpacks Complicated Regulatory Path Forward

October 11, 2023 | markets.businessinsider.com

Optimistic Outlook for Akero Therapeutics’ EFX Despite SYMMETRY Study Setback: Dolezal’s Perspective

October 10, 2023 | msn.com

Akero slumps leading to mixed reactions in NASH space

October 10, 2023 | markets.businessinsider.com

Akero Therapeutics' Disappointing NASH Data Drags Its Rival

October 10, 2023 | finance.yahoo.com

Why Akero Therapeutics Lost More Than Half Its Value And Dragged Down 89bio

October 10, 2023 | finance.yahoo.com

Why Shares of 89bio Plummeted on Tuesday

October 10, 2023 | msn.com

Akero Therapeutics: Contrarian Buy Opportunity As Stock Tanks On 'NASH Dash' Data

October 10, 2023 | markets.businessinsider.com

Why Is Liver Disease Focused Akero Therapeutics Stock Sinking Today?

October 10, 2023 | finance.yahoo.com

Why Akero Therapeutics Stock Is Crashing Today

October 10, 2023 | investorplace.com

Why Is Akero Therapeutics (AKRO) Stock Down 58% Today?

See More Headlines

Receive AKRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/13/2023
Today: 11/29/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/15/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AKRO
CUSIP: N/A
CIK: 1744659
Web: www.akerotx.com
Phone: (650) 487-6488
Fax: N/A
Employees: 51
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $40.86
High Stock Price Target: $58.00
Low Stock Price Target: $33.00
Potential Upside/Downside: +147.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.35)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-112,030,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -26.11%
Return on Assets: -23.87%

Debt

Debt-to-Equity Ratio: 0.04
Current Ratio: 20.25
Quick Ratio: 20.25

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.98 per share
Price / Book: 2.37

Miscellaneous

Outstanding Shares: 55,710,000
Free Float: 50,312,000
Market Cap: $920.33 million
Optionable: Not Optionable
Beta: -0.73

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Dr. Andrew Cheng M.D. (Age 56)
Ph.D., President, CEO & Director
Comp: $1.22M
Dr. Jonathan M. Young J.D. (Age 53)
Ph.D., Co-Founder, Executive VP, COO & Secretary
Comp: $763.3k
Dr. Timothy Rolph (Age 69)
Co-Founder & Chief Scientific Officer
Comp: $819.4k
Mr. William R. White J.D. (Age 50)
Executive VP, CFO, Treasurer & Head of Corporate Development
Comp: $768.4k
Ms. Catriona Yale (Age 51)
Executive VP & Chief Development Officer
Comp: $754.8k
Mr. Patrick Lamy (Age 50)
Senior Vice President of Commercial Strategy
Mr. John J. Schembri (Age 61)
VP of Finance & Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AKRO Stock Analysis - Frequently Asked Questions

Should I buy or sell Akero Therapeutics stock right now?: 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Akero Therapeutics in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AKRO shares.
View AKRO analyst ratings or view top-rated stocks.
What is Akero Therapeutics' stock price target for 2024?: 8 brokers have issued twelve-month target prices for Akero Therapeutics' shares. Their AKRO share price targets range from $33.00 to $58.00. On average, they predict the company's share price to reach $40.86 in the next year. This suggests a possible upside of 147.3% from the stock's current price.
View analysts price targets for AKRO or view top-rated stocks among Wall Street analysts.
How have AKRO shares performed in 2023?: Akero Therapeutics' stock was trading at $54.80 at the beginning of 2023. Since then, AKRO shares have decreased by 69.9% and is now trading at $16.52.
View the best growth stocks for 2023 here.
When is Akero Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, March 15th 2024.
View our AKRO earnings forecast.
How were Akero Therapeutics' earnings last quarter?: Akero Therapeutics, Inc. (NASDAQ:AKRO) released its earnings results on Monday, November, 13th. The company reported ($0.71) earnings per share for the quarter, missing analysts' consensus estimates of ($0.70) by $0.01.
What ETFs hold Akero Therapeutics' stock?: ETFs with the largest weight of Akero Therapeutics (NASDAQ:AKRO) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), ALPS Medical Breakthroughs ETF (SBIO) and SPDR S&P Biotech ETF (XBI).Invesco DWA SmallCap Momentum ETF (DWAS).

What other stocks do shareholders of Akero Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Akero Therapeutics investors own include Fulcrum Therapeutics (FULC), Kaleido Biosciences (KLDO), Sorrento Therapeutics (SRNE), Editas Medicine (EDIT), Gossamer Bio (GOSS), Provention Bio (PRVB), Alector (ALEC), Micron Technology (MU), VIVUS (VVUS).
When did Akero Therapeutics IPO?: (AKRO) raised $75 million in an initial public offering (IPO) on Thursday, June 20th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and Evercore ISI served as the underwriters for the IPO and Roth Capital Partners was co-manager.
Who are Akero Therapeutics' major shareholders?: Akero Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Alkeon Capital Management LLC (6.78%), FMR LLC (4.95%), Adage Capital Partners GP L.L.C. (3.49%), Redmile Group LLC (3.18%), Rock Springs Capital Management LP (2.55%) and Lord Abbett & CO. LLC (1.40%). Insiders that own company stock include Andrew Cheng, Catriona Yale, G Walmsley Graham, Jonathan Young, Kevin Bitterman, Seth Loring Harrison, Skorpios Trust, Timothy Rolph, Tomas J Heyman and William Richard White.
View institutional ownership trends.
How do I buy shares of Akero Therapeutics?: Shares of AKRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:AKRO) was last updated on 11/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Akero Therapeutics Stock Price, News & Analysis (NASDAQ:AKRO)

Akero Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Akero Therapeutics Stock (NASDAQ:AKRO)

AKRO Stock Price History

AKRO Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

AKRO Stock Analysis - Frequently Asked Questions

Overall MarketRank^™